share_log

One CSPC Pharmaceutical Group Insider Raised Their Stake In The Previous Year

One CSPC Pharmaceutical Group Insider Raised Their Stake In The Previous Year

一位CSPC製藥集團內部人士在去年籌集了股份
Simply Wall St ·  01/27 19:36

Looking at CSPC Pharmaceutical Group Limited's (HKG:1093 ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.

縱觀去年石藥集團有限公司(HKG: 1093)的內幕交易,我們可以看到內部人士是淨買家。也就是說,內部人士購買的股票數量多於出售的股票數量。

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

儘管在長期投資中,內幕交易並不是最重要的事情,但我們認爲完全忽視內幕交易是愚蠢的。

View our latest analysis for CSPC Pharmaceutical Group

查看我們對石藥集團的最新分析

CSPC Pharmaceutical Group Insider Transactions Over The Last Year

CSPC製藥集團去年的內幕交易

Over the last year, we can see that the biggest insider purchase was by Executive Chairman Dongchen Cai for HK$13m worth of shares, at about HK$7.69 per share. That means that an insider was happy to buy shares at above the current price of HK$5.99. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Dongchen Cai was the only individual insider to buy during the last year.

在過去的一年中,我們可以看到,最大的內幕收購是執行主席蔡東晨以每股約7.69港元的價格購買了價值1300萬港元的股票。這意味着內部人士樂於以高於當前5.99港元的價格購買股票。從那以後,他們的觀點可能發生了變化,但至少這表明他們當時感到樂觀。對我們來說,考慮內部人士爲股票支付的價格非常重要。令人鼓舞的是,一位內部人士的股價高於當前的股價,這表明即使在更高的水平上,他們也看到了價值。蔡東晨是去年唯一買入的內部人士。

Dongchen Cai bought 4.25m shares over the last 12 months at an average price of HK$7.59. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

蔡東晨在過去的12個月中以7.59港元的平均價格購買了425萬股股票。您可以看到下圖所示的去年的內幕交易(公司和個人)。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!

insider-trading-volume
SEHK:1093 Insider Trading Volume January 28th 2024
SEHK: 1093 內幕交易量 2024 年 1 月 28 日

CSPC Pharmaceutical Group is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

CSPC製藥集團並不是內部人士唯一買入的股票。對於那些喜歡尋找中獎投資的人來說,這份最近有內幕收購的成長型公司的免費名單可能只是門票。

Insider Ownership

內部所有權

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. CSPC Pharmaceutical Group insiders own about HK$17b worth of shares (which is 24% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

查看公司的內部持股總量可以幫助你了解他們是否與普通股股東保持一致。我認爲,如果內部人士擁有該公司的大量股份,這是一個好兆頭。石藥集團內部人士擁有價值約170億港元的股份(佔該公司24%的股份)。大多數股東會很高興看到這種內部所有權,因爲這表明管理層的激勵措施與其他股東非常一致。

So What Do The CSPC Pharmaceutical Group Insider Transactions Indicate?

那麼,CSPC製藥集團的內幕交易表明了什麼?

It doesn't really mean much that no insider has traded CSPC Pharmaceutical Group shares in the last quarter. However, our analysis of transactions over the last year is heartening. It would be great to see more insider buying, but overall it seems like CSPC Pharmaceutical Group insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. While conducting our analysis, we found that CSPC Pharmaceutical Group has 1 warning sign and it would be unwise to ignore it.

上個季度沒有內部人士交易過CSPC製藥集團的股票,這並不意味着什麼。但是,我們對去年交易的分析令人鼓舞。很高興看到更多的內幕收購,但總體而言,CSPC Pharmaceutical Group的內部人士似乎相當一致(擁有該公司的很大一部分股份),對未來持樂觀態度。因此,這些內幕交易可以幫助我們建立有關股票的論點,但也值得了解該公司面臨的風險。在進行分析時,我們發現CSPC製藥集團有1個警告信號,忽視它是不明智的。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果你想看看另一家公司——一家財務狀況可能優越的公司——那麼千萬不要錯過這份免費的股本回報率高、債務低的有趣公司的名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論